Cited by 206Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Open access

Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A., Haura, Eric, Politi, Katerina, Glisson, Bonnie, Cetnar, Jeremy, Garon, Edward B., Schiller, Joan, Waqar, Saiama N., Sequist, Lecia V., Brahmer, Julie, Shyr, Yu, Kugler, Kelly, Wistuba, Ignacio I., Johnson, Bruce E., Minna, John D., Kris, Mark G., Bunn, Paul A., Kwiatkowski, David J.·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2289PMC PMC7008001

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: Multiplex genomic profiling is standard of care for patients with advanced lung adenocarcinomas. The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas. Experimental Design: Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC. Results: The use of targeted therapies in patients with EGFR, ERBB2, or BRAF p.V600E mutations, ALK, ROS1, or RET rearrangements, or MET amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver. Importantly, 60 patients with a history of smoking derived similar survival benefit from targeted therapy for alterations in EGFR/ALK/ROS1, when compared with 75 never smokers with the same alterations. In addition, coexisting TP53 mutations were associated with shorter survival among patients with EGFR, ALK, or ROS1 alterations. Conclusion: Patients with adenocarcinoma of the lung and an oncogenic driver mutation treated with effective targeted therapy have a longer survival, regardless of prior smoking history. Molecular testing should be performed on all individuals with lung adenocarcinomas irrespective of clinical characteristics. Routine use of massively parallel sequencing enables detection of both targetable driver alterations and tumor suppressor gene and other alterations that have potential significance for therapy selection and as predictive markers for the efficacy of treatment. Clin Cancer Res; 24(5); 1038–47. ©2017 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2289

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2017.
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citation
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Self-citation
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
p53 mutations in cancer
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Self-citation
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,373
Self-citation
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,315
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Self-citation
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Self-citation
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Barlési, F., Mazières, J., Merlio, J., Debieuvre, D., Mosser, J., Léna, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,000
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Self-citation
TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
Poeta, M. L., Manola, J. B., Goldwasser, M. A., Forastiere, A. A., Benoit, N. E., Califano, J. A., Ridge, J. A., Goodwin, J. W., Kenady, D. E., Saunders, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073770 · Cited by 818
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Frampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Awad, M. M., Oxnard, G. R., Jackman, D. M., Savukoski, D. O., Hall, D., Shivdasani, P., Heng, J. C., Dahlberg, S. E., Janne, P. A., Verma, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4600 · Cited by 714
Self-citation
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643
Self-citation
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paik, P. K., Drilon, A. E. D. C., Fan, P., Yu, H. A., Rekhtman, N., Ginsberg, M. S., Borsu, L. A., Schultz, N. D., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 583
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 561
Self-citation
A Genomics-Based Classification of Human Lung Tumors
Thomas, R. K., Buettner, R., & Wolf, J. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 516
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Self-citation
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Self-citation
Institutional implementation of clinical tumor profiling on an unselected cancer population
Sholl, L. M., Do, K., Shivdasani, P., Cerami, E., Dubuc, A. M., Kuo, F. C., Garcia, E. P., Jia, Y., Davineni, P., Abo, R. P., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87062 · Cited by 450
Self-citation
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Self-citation
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Meric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424
Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Gautschi, O. P., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D. H., Camidge, D. R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 364
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Liu, X., Jia, Y., Stoopler, M. B., Shen, Y., Cheng, H., Chen, J., MANSUKHANI, M. M., Koul, S., Halmos, B., & Borczuk, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0674 · Cited by 350
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Spigel, D. R., Edelman, M. J., O'Byrne, K. J., Paz-Ares, L. G., Mocci, S., Phan, S. C., Shames, D. S., Smith, D., Yu, W., Paton, V. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2160 · Cited by 336
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Self-citation
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
Camidge, D. R., Ou, S. I., Shapiro, G. I., Otterson, G. A., Villaruz, L. C., Villalona-Calero, M. A., Iafrate, A. J., Varella‐Garcia, M., Đačić, S., Cardarella, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8001 · Cited by 256
Self-citation
Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
Li, C., Fang, R., Sun, Y., Han, X., Li, F., Gao, B., Iafrate, A. J., Liu, X.-Y., Pao, W. J., Chen, H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028204 · Cited by 230
Self-citation
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
Patnaik, A., Appleman, L., Tolcher, A., Papadopoulos, K., Beeram, M., Rasco, D., Weiss, G., Sachdev, J., Chadha, M., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 218
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Go, H., Jeon, Y. K., Park, H. J., Sung, S.-W., Seo, J., & Chung, D. H. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ce3d1d · Cited by 217
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203
Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
VanderLaan, P. A., Rangachari, D., Mockus, S. M., Spotlow, V., Reddi, H. V., Malcolm, J., Huberman, M. S., Joseph, L. J., Kobayashi, S. S., & Costa, D. B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.011 · Cited by 190
Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer
Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gascó, A., Mayo‐de‐las‐Casas, C., Sanchez-Ronco, M., Pujantell-Pastor, L., Bonanno, L., Favaretto, A. G., Cardona, A. F., Vergnenégre, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2391 · Cited by 186
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Dziadziuszko, R., Wynes, M. W., Singh, S., Asuncion, B. R., Ranger‐Moore, J., Konopa, K., Rzyman, W., Szostakiewicz, B., Jassem, J., & Hirsch, F. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318240ca0d · Cited by 156
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Self-citation
Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E. M., Rangell, L. K., Raja, R. G., Mohan, S., Patel, R., Desai, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1836 · Cited by 136
Self-citation
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the L ung C ancer M utation C onsortium
Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 127
Self-citation
EGFR Exon 18 Mutations in Lung Cancer：Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
祥久, 小. (2017) · Cited by 114
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado‐Coll, A., Troyer, D. A., McKenney, J. K., Simko, J. P., Carroll, P. R., et al. (2015) · European Urology Focus · doi:10.1016/j.euf.2015.07.005 · Cited by 76
Kinase gene fusions in defined subsets of melanoma
Turner, J. A., Couts, K. L., Sheren, J. E., Saichaemchan, S., Ariyawutyakorn, W., Avolio, I., Cabral, E., Glogowska, M., Amato, C. M., Robinson, S. E., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12560 · Cited by 53
FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm564331.htm · Cited by 10

Sorted by citations

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,656
Self-citation
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Review of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 803
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686
Self-citation
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 520

See all 206

Authors: Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., Haura, E., Politi, K., Glisson, B., Cetnar, J., Garon, E. B., Schiller, J., Waqar, S. N., Sequist, L. V., Brahmer, J., Shyr, Y., Kugler, K., Wistuba, I. I., Johnson, B. E., Minna, J. D., Kris, M. G., Bunn, P. A., & Kwiatkowski, D. J.
Affiliations: University of Colorado Cancer Center (US)
Brigham and Women's Hospital (US)
Vanderbilt-Ingram Cancer Center (US)
Emory University (US)
The University of Texas MD Anderson Cancer Center (US)
Memorial Sloan Kettering Cancer Center (US)
University of Pittsburgh (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Moffitt Cancer Center (US)
Yale University (US)
Oregon Health & Science University (US)
University of California, Los Angeles (US)
The University of Texas Southwestern Medical Center (US)
Washington University in St. Louis (US)
Massachusetts General Hospital (US)
Johns Hopkins University (US)
Dana-Farber Cancer Institute (US)
Corresponding author: Aisner, Dara L.
Kwiatkowski, David J.
ORCID: Aisner, Dara L.
Sholl, Lynette M.
Berry, Lynne D.
Rossi, Michael R.
Chen, Heidi
Fujimoto, Junya
Moreira, Andre L.
Ramalingam, Suresh S.
Villaruz, Liza C.
Otterson, Gregory A.
Haura, Eric
Politi, Katerina
Glisson, Bonnie
Garon, Edward B.
Schiller, Joan
Waqar, Saiama N.
Sequist, Lecia V.
Brahmer, Julie
Shyr, Yu
Wistuba, Ignacio I.
Johnson, Bruce E.
Minna, John D.
Kris, Mark G.
Bunn, Paul A.
Kwiatkowski, David J.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-02-28
Volume: 24
Issue: 5
Pages: 1038-1047
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2289
PMC: PMC7008001
OpenAlex: W2775798067
Cited by: 206
References: 54
Citations by year: 2026: 8 · 2025: 11 · 2024: 15 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 38 · 2019: 29 · 2018: 26
FWCI: 21.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Free To Breathe
National Cancer Institute (R01CA208403, P30CA008748, P30CA046934)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: lung adenocarcinoma, smoking history, TP53 mutation, targeted therapy, EGFR mutation, ALK rearrangement, ROS1 rearrangement, BRAF V600E mutation, MET amplification, survival, molecular testing, tumor suppressor, predictive biomarkers
MeSH terms: Adenocarcinoma of Lung, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, DNA Mutational Analysis, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Prospective Studies, Smoking, Biomarkers, Tumor, Survival Analysis, Tumor Suppressor Protein p53, Treatment Outcome, Young Adult, Molecular Targeted Therapy, High-Throughput Nucleotide Sequencing, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks